bivv001

Trade name: Advate

Recombinant proteinexperimental

Clinical trial activity

14 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
6
Phase 3
5
Phase 4
4

Earliest trial started Mar 3, 2016 (NCT02716194)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Availability
Prescription Only
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bax 826

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07158606Phase 4Oct 1, 2025Versiti
NCT06941870Phase 4Sep 23, 2025Sanofi
NCT06940830Phase 4May 21, 2025PSI CRO, Swedish Orphan Biovitrum
NCT06716814Phase 3Jan 31, 2025PSI CRO, Swedish Orphan Biovitrum
NCT06752850Phase 4Dec 19, 2024PSI CRO, Swedish Orphan Biovitrum
NCT06579144Phase 1Nov 30, 2024PSI CRO, Swedish Orphan Biovitrum
NCT05817812Phase 3Jul 31, 2023Swedish Orphan Biovitrum, Syneos Health
NCT05042440Phase 1Aug 11, 2021Sanofi
NCT04770935Phase 1May 3, 2021Sanofi, Sanofi-Aventis
NCT04759131Phase 3Feb 19, 2021Sanofi, Sanofi-Aventis
NCT04644575Phase 3Jan 19, 2021Sanofi, Sanofi-Aventis
NCT04161495Phase 3Dec 5, 2019Sanofi
NCT03205163Phase 1/Phase 2 (Phase 2)Jul 31, 2017Bioverativ Therapeutics Inc.
NCT02716194Phase 1Mar 3, 2016Baxalta
Showing 14 of 14 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
SanofiFor profit6332019
Swedish Orphan BiovitrumFor profit5532023
PSI CROFor profit4032024
Sanofi-AventisFor profit3322021
BaxaltaFor profit1112016
Bioverativ Therapeutics Inc.For profit1112017
Syneos HealthFor profit1012023
VersitiAcademic/Hospital1112025
8 organizations
Page 1 / 1